Haemostatic Balance and Transfusion Strategies in Acute Liver Failure and Acute-On-Chronic Liver Failure: A Systematic Review

IF 5.2 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Kymentie Ferdinande, Elena Campello, Paolo Simioni, Alberto Zanetto, Marco Senzolo
{"title":"Haemostatic Balance and Transfusion Strategies in Acute Liver Failure and Acute-On-Chronic Liver Failure: A Systematic Review","authors":"Kymentie Ferdinande,&nbsp;Elena Campello,&nbsp;Paolo Simioni,&nbsp;Alberto Zanetto,&nbsp;Marco Senzolo","doi":"10.1111/liv.70378","DOIUrl":null,"url":null,"abstract":"<p>Patients with acute-on-chronic liver failure (ACLF) and acute liver failure (ALF) exhibit complex hemostatic changes with a ‘rebalanced’ but fragile equilibrium, predisposing them to both bleeding and thrombosis. This review assesses hemostatic profiles, bleeding and thrombotic complications, and management strategies involving blood products in both ACLF and ALF. We conducted a systematic review in PubMed, EMBASE, and Web of Science, identifying 57 studies that addressed the coagulation status and the use of blood products and anticoagulants in ACLF and ALF. Study selection, data extraction and quality assessment were performed by two independent reviewers. In ACLF, global hemostatic assays reveal preserved thrombin generation (TG) alongside hypocoagulability on viscoelastic testing (VETs). Bleeding incidence varies widely (7.35%–67%), as do thrombotic events (4,7%–20%). Prophylactic correction of coagulation abnormalities is discouraged with bleeding management prioritized based on individualized risk assessment, guided by VET. Prophylactic anticoagulation remains controversial, while direct oral anticoagulants are contraindicated. In ALF, despite markedly elevated INR, TG assay and VET indicated preserved hemostatic balance, with hypercoagulability in some patients and true hypocoagulability rarely observed. Bleeding complications occur in 7,4%–18%, while thrombotic complications occur in 6%–21%. Routine INR correction is not recommended; VET may guide procedural/therapeutic decisions. No clear recommendations can be given for thromboprophylaxis. In conclusion, the complex coagulation landscape in ACLF and ALF underscores the need for individualized management balancing hemorrhagic and thrombotic risks. The absence of reliable hemostatic assays to guide prophylactic anticoagulation remains a critical gap. In these high-risk patients, the integration of VET into personalized coagulation assessment might be considered to support individualized bleeding management and transfusion strategies, although further investigation is warranted.</p>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 11","pages":""},"PeriodicalIF":5.2000,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.70378","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver International","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/liv.70378","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Patients with acute-on-chronic liver failure (ACLF) and acute liver failure (ALF) exhibit complex hemostatic changes with a ‘rebalanced’ but fragile equilibrium, predisposing them to both bleeding and thrombosis. This review assesses hemostatic profiles, bleeding and thrombotic complications, and management strategies involving blood products in both ACLF and ALF. We conducted a systematic review in PubMed, EMBASE, and Web of Science, identifying 57 studies that addressed the coagulation status and the use of blood products and anticoagulants in ACLF and ALF. Study selection, data extraction and quality assessment were performed by two independent reviewers. In ACLF, global hemostatic assays reveal preserved thrombin generation (TG) alongside hypocoagulability on viscoelastic testing (VETs). Bleeding incidence varies widely (7.35%–67%), as do thrombotic events (4,7%–20%). Prophylactic correction of coagulation abnormalities is discouraged with bleeding management prioritized based on individualized risk assessment, guided by VET. Prophylactic anticoagulation remains controversial, while direct oral anticoagulants are contraindicated. In ALF, despite markedly elevated INR, TG assay and VET indicated preserved hemostatic balance, with hypercoagulability in some patients and true hypocoagulability rarely observed. Bleeding complications occur in 7,4%–18%, while thrombotic complications occur in 6%–21%. Routine INR correction is not recommended; VET may guide procedural/therapeutic decisions. No clear recommendations can be given for thromboprophylaxis. In conclusion, the complex coagulation landscape in ACLF and ALF underscores the need for individualized management balancing hemorrhagic and thrombotic risks. The absence of reliable hemostatic assays to guide prophylactic anticoagulation remains a critical gap. In these high-risk patients, the integration of VET into personalized coagulation assessment might be considered to support individualized bleeding management and transfusion strategies, although further investigation is warranted.

Abstract Image

急性肝衰竭和急性-慢性肝衰竭的止血平衡和输血策略:系统综述
急性慢性肝功能衰竭(ACLF)和急性肝功能衰竭(ALF)患者表现出复杂的止血变化,具有“再平衡”但脆弱的平衡,易导致出血和血栓形成。本综述评估了ACLF和ALF患者的止血概况、出血和血栓并发症以及涉及血液制品的管理策略。我们在PubMed、EMBASE和Web of Science上进行了系统综述,确定了57项研究,这些研究涉及ACLF和ALF的凝血状态、血液制品和抗凝剂的使用。研究选择、数据提取和质量评估由两名独立评审员完成。在ACLF中,整体止血分析显示粘弹性测试(vet)中保留了凝血酶生成(TG)和低凝性。出血发生率差异很大(7.35%-67%),血栓形成事件也是如此(4.7% - 20%)。不鼓励对凝血异常进行预防性纠正,在VET的指导下,根据个体化风险评估优先进行出血管理。预防性抗凝仍有争议,而直接口服抗凝剂是禁忌。在ALF患者中,尽管INR明显升高,但TG和VET显示止血平衡保持,部分患者存在高凝性,很少观察到真正的低凝性。出血并发症发生率为7.4% - 18%,血栓性并发症发生率为6%-21%。不建议常规INR校正;VET可以指导程序/治疗决策。对于血栓预防没有明确的建议。总之,ACLF和ALF复杂的凝血情况强调了平衡出血和血栓风险的个体化管理的必要性。缺乏可靠的止血试验来指导预防性抗凝仍然是一个关键的空白。在这些高危患者中,尽管需要进一步的研究,但将VET纳入个性化凝血评估可能会被认为支持个性化的出血管理和输血策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Liver International
Liver International 医学-胃肠肝病学
CiteScore
13.90
自引率
4.50%
发文量
348
审稿时长
2 months
期刊介绍: Liver International promotes all aspects of the science of hepatology from basic research to applied clinical studies. Providing an international forum for the publication of high-quality original research in hepatology, it is an essential resource for everyone working on normal and abnormal structure and function in the liver and its constituent cells, including clinicians and basic scientists involved in the multi-disciplinary field of hepatology. The journal welcomes articles from all fields of hepatology, which may be published as original articles, brief definitive reports, reviews, mini-reviews, images in hepatology and letters to the Editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信